AIDS in Africa "$1,120/pa to treat each patient"

5 April 2001

Treating three million AIDS patients in sub-Saharan Africa would costmore than $3.3 billion per annum for three years, say Harvard University faculty members. Each patient would cost $1,120 a year to treat, including drugs, testing, monitoring and research, they say, but not including other treatment and prevention programs, which would cost an additional $3 billion a year for only one million people. By the fifth year, total costs of treatment and prevention for three million people would reach around $6.3 billion a year, they add.

Three-four million people in sub-Saharan Africa are in the advanced stages of AIDS, but only about 10,000 have access to antiretroviral drug therapies, says the Harvard report, which adds that clinical trials should be conducted to determine optimum HIV treatment in these countries.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight